Abstract: The present disclosure related to a system, method and device for distributing messages to electronic devices is provided. The method comprises: identifying two devices that have been communicating with each other and that have at least one common attribute; identifying an advertisement campaign that matches the at least one common attribute; and transmitting a set of advertisements relating to the advertisement campaign to the two devices.

Abstract: Addresses are searched in an address book on a communication device in response to various context information. A category is defined from a keyword. A context is determined. The address book is searched using the keywords and/or category and or/context to locate matching contacts. Matching contacts may be presented in a user interface, e.g., in accordance with presentation rules responsive to the context. The method may further look-up (and present) one or more addresses (e.g. advertisements) matching the keyword and/or category and/or context from a remote service. The context may be data defined from any of time, day of the week, communication device location, communication device velocity, device profile and category of a matching contact. Device profile may be determined using profile determining rules and contextual data. The method may periodically collect contextual data and define a profile determining rule in response to a pattern in the collected data.

Abstract: The present disclosure described herein relates to a system and method for distributing messages to electronic devices. The method comprises: identifying a set of devices that meet a first criteria regarding an activity level; and transmitting a set of advertisements to the set of devices based on activity levels of the set of devices. For at least one of the devices, the activity data may relate to at least one communication log of communications processed by at least one device.

Abstract: The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula wherein Y and R1 to R4 are defined as in claim 1, the tautomers, enantiomers, diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention provides a pharmaceutical composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs. The invention further provides respective uses of such compositions and of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or pharmaceutically acceptable forms thereof.

Abstract: Systems and methods are provided for providing and displaying enhanced banners and other objects on a communication device. The banner file may comprise ancillary data, such as calendar appointment details, other event details, or contact details, embedded within the file itself, or comprised in an envelope wrapping the banner file. When the banner is displayed on the communication device, the user may invoke a context menu to create an event, such as a calendar event, on the device using the embedded ancillary data. In other embodiments, the communication device uses geolocation services to determine whether the user is likely to be in attendance at an event, and if not, to issue alerts or initiate a further action, such as initiating recording of a television program the user is about to miss, over the network. In other embodiments, the banner file's ancillary data includes recommendation data, identifying a banner as being recommended by a contact of the user's.

Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: A method for the prevention or treatment of a cardiovascular, cardiopulmonary, or renal disease or condition in a human or mammal patient, the method comprising administering to the patient in need thereof an effective amount of: (a) telmisartan or a polymorph or salt thereof; and (b) simvastatin.

Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for wound healing preferably in diabetic patients.

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are defined as in claim 1, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R4 are as defined herein, the tautomers and the stereoisomers thereof, mixtures thereof, the prodrugs and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Abstract: The specification describes the use of selected purine derivatives for the treatment of hyperproliferative diseases.

Abstract: The invention relates to a pharmaceutical composition according to claim 1 comprising a SGLT2 inhibitor in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing non alcoholic fatty liver diseases (NAFLD).

Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor, a DPPIV inhibitor and a third antidiabetic agent which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a SGLT-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

Abstract: A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug, a poorly aqueous soluble non-ionizable cellulosic polymer, and a poorly aqueous soluble polymeric amphiphilic non-ionizable block copolymer.

Abstract: Compounds of formula (I) wherein R1 is a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by R10 and R11 and R2 to R4 and R10 and R1l are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type II diabetes mellitus and obesity using these compounds.

Abstract: A pharmaceutical composition comprises nanoparticles comprising ionizable, poorly water soluble cellulosic polymers.